康莱特联合化疗腔内注射治疗恶性胸腔积液的Meta分析.pdfVIP

康莱特联合化疗腔内注射治疗恶性胸腔积液的Meta分析 胡正波 ，卢海波，徐春红，胡露（解放军第452医院，成都 610021） 摘要：目的：系统评价康莱特联合化疗药物胸腔内灌注治疗恶性胸腔积液的疗效和安全性。方法： 计算机检索Cochrane图书馆、EMbase、PubMed、中国期刊全文数据库(CNKI)、中国生物医学文 献数据库(CBM)、中文科技期刊全文数据库(VIP)，按照纳入与排除标准，制定检索策略，全面收 康莱特联合化疗药物胸腔内灌注治疗恶性胸腔积液的随机对照试验(RCT)，对纳入研究进行质 量评价后，采用RevMan5.14统计学软件进行Meta分析。结果：共纳入13项RCT，合计537例患者。 Meta分析结果显示，治疗组近期有效率更高[RR=1.43,95%CI(1.28,1.59),P0.01]；治疗组生存质量 改善率[RR=1.09,95%CI(0.94,1.28),P=0.25]与对照组比较，差异无统计学意义。治疗组胃肠道反应、 胸痛的发生率显著优于对照组(P＜0.01)；治疗组肾功能异常、骨髓毒性、发热的发生率与对照组 比较，差异无统计学意义。结论：康莱特联合化疗药方案较单纯使用化疗药更有效，并能降低部 分毒副作用。但由于纳入的研究质量较低，本结论尚需要更多高质量、大样本的研究予以证实。 关键词：康莱特；恶性胸腔积液；Meta分析 Meta-analysis ofIntrapleuralInjection ofKanglaite Combinedwith ChemotherapyintheTreatmentofMalignantpleuraleffusion. HUZheng-bo,LIPeng,XUChun-hong,HULu （The452hospitalofPLA,Chengdu,Sichuan,610021） Abstract: Objective To evaluate the efficacy and safety of intrapleural injection kanglaite combined with chemotherapy in the treatment of malignant pleural effusion. Methods Retrieved from Cochrane library,EMbase, PubMed,CNKI,CBM,VIP, a ording to include and exclude criterion,RCT about intrapleural injection kanglaite combined with chemotherapy in the treatment of malignant pleural effusionwerecollected.QualitywasevaluatedandMeta-analysiswascarriedout.Results 13RCTwere included, involving 537patients in total. Meta-analysis indicated that effective rate oftreatment group was significantly higher than control group[RR=1.43,95%CI(1.28,1.59), P0.01], there was no statistical significance between 2 groups in quality of life[RR=1.09,95%CI(0.94,1.28),P=0.25]. The incidenceofgastrointestinalreaction andchestpain intreatment groupwere significantlylowerthan in 作者简介：胡正波，硕士，副主任药师。研究方向：药事管理、临床药学。电话：028 E-mail:huzhengbo136@ 259 control group (P ＜0.01). There were no statistical significance between 2 groups in incidence of dysfunction of kidney, hypodynamia and fever. Conclusion Intrapleural injection Kangla